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What is the key question?!
Although COPD independently increases the risk for NSCLC up to fivefold, it has not 
been established how COPD influences NSCLC development and tumor progression. !
What is the bottom line?!$ung tumors in COPD patients are, in contrast to those from non-COPD patients, 
characterized by an immune-related signature as revealed by unbiased DNA 
methylation profiling, and confirmed by gene expression profiling and 
immunohistochemistry.!
Why read on?!
The identified immune-related signature in COPD-associated NSCLC may contribute 
to the optimization of novel NSCLC treatment strategies by assisting in treatment 
stratification and prediction of treatment response. 
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ABSTRACT 
Introduction Non-small cell lung cancer (NSCLC) is a heterogeneous disorder 
consisting of distinct molecular subtypes each characterized by specific genetic and 
epigenetic profiles. Here, we aimed to identify novel NSCLC subtypes based on 
genome-wide methylation data, assess their relationship with smoking behavior, age, 
chronic obstructive pulmonary disease (COPD), emphysema and tumor 
histopathology, and identify the molecular pathways underlying each subtype. 
Methods Methylation profiling was performed on 49 pairs of tumor and adjacent lung 
tissue using Illumina 450K arrays. Transcriptome sequencing was performed using 
Illumina HiSeq2000 and validated using expression data from The Cancer Genome 
Atlas (TCGA). Tumor immune cell infiltration was investigated by 
immunohistochemistry. 
Results Unsupervised hierarchical clustering of tumor methylation data revealed 2 
subgroups characterized by a significant association between cluster membership and 
presence of COPD (P=0.024). Ontology analysis of genes containing differentially 
methylated CpGs (FDR-adjusted P<0.05) revealed that immune genes were strongly 
enriched in COPD tumors, but not in non-COPD tumors. This COPD-specific 
immune signature was attributable to methylation changes in immune genes 
expressed either by tumor cells or tumor-infiltrating immune cells. No such 
differences were observed in adjacent tissue. Transcriptome profiling similarly 
revealed that genes involved in the immune response were differentially expressed in 
COPD tumors (FDR-adjusted P<0.05), an observation that was independently 
replicated using TCGA data. Immunohistochemistry validated these findings, 
revealing fewer CD4-positive T-lymphocytes in tumors derived from COPD patients.  
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Conclusions Lung tumors of COPD patients differ from those of non-COPD patients, 




Lung cancer is the leading cause of cancer-related death worldwide with an 
alarmingly low 5-year survival rate of <15%. Therapies targeting specific genetic 
lesions in the tumor are increasingly being used to treat lung cancer, highlighting the 
need to accurately classify lung tumors based on their molecular-genetic 
composition.1 Similar to somatic mutations, epigenetic modifications may provide a 
substrate for clonal selection during malignant transformation. As such, genome-wide 
methylation profiling studies can identify signatures that contribute to the molecular 
sub-classification of various cancers.2 For instance, methylation profiling classifies 
breast tumors into its four established expression subtypes and already identified an 
additional subtype associated with T-lymphocyte infiltration and favorable outcome.3 
Over 50% of lung cancer patients also suffer from chronic obstructive 
pulmonary disease (COPD) due to shared risk factors, such as age and cigarette 
smoking.4 However, COPD also independently increases the risk for lung cancer up 
to fivefold.5 Although genetic association studies revealed susceptibility variants 
overlapping between both diseases,6,7 the precise mechanisms underlying this link are 
incompletely understood.8 Here, we hypothesize that the inflammatory 
microenvironment in COPD lungs, which results from a maladaptive response of the 
immune system to inhaled noxious particles, may influence lung cancer development 
through its impact on the epigenome. Indeed, amongst various biological processes, 
changes in immune response-related genes were recently observed in peripheral blood 
leucocytes and bronchial small airway epithelial cells of cancer-free smokers with 
COPD.9 Likewise, age-related CpG island hypermethylation in non-malignant human 
tissues and gene-specific hypomethylation in blood of active smokers have been 
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described.10 Surprisingly, although lung cancer-specific methylation profiles have 
previously been generated, the potential contributions of COPD, age and smoking 
history to these signatures have not been assessed. 
 
METHODS 
Additional details can be found in the online supplement. 
Study participants 
We prospectively recruited untreated NSCLC patients scheduled for curative-intent 
surgery and a smoking history of ?15 pack-years at the Leuven University Hospital 
(Belgium) between March 2010 and August 2011. Prior to surgery, all 49 eligible 
participants performed spirometry according to the American Thoracic Society and 
European Respiratory Society guidelines.11 COPD was defined as post-bronchodilator 
FEV1/FVC<0.70 and staged according GOLD 2007 guidelines.12 Emphysema was 
semi-quantitatively assessed by a radiologist, as described previously.6,7 Other 
respiratory diseases affecting pulmonary function were excluded. Previous treatments 
for COPD were retrieved from electronic medical files. The study protocol was 
approved by the local ethical committee. All participants provided written informed 
consent. 
DNA isolation and methylation profiling 
DNA was extracted from fresh-frozen tumor tissue, in which !70% of the epithelial 
cells were malignant based on histological examination, and adjacent lung tissue from 
the same resection specimen at maximal distance (>5cm) from the tumor. Bisulfite-
converted DNA was hybridized on 450K BeadChips, using the Infinium HD 
Methylation protocol. After controlling for batch effect and normalizing raw intensity 
data, the methylation level of each interrogated CpG, scored as a "-value between 0 
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and 1, was calculated according to the fluorescent intensity ratio. 
RNA extraction and transcriptome sequencing  
Total RNA was extracted from all tumor samples undergoing methylation profiling. 
RNA sequencing was performed using Illumina HiSeq2000. In addition, RNA 
sequencing data of tumor and adjacent lung tissue samples of 178 NSCLC patients 
were downloaded from the TCGA portal (https://tcga-data.nci.nih.gov/tcga/). 
Histological analyses 
An experienced pathologist blinded to the clinical data semi-quantitatively scored 
hematoxylin and eosin (H&E)-stained tumor sections for immune cell infiltrates, as 
no-to-mild or moderate-to-severe infiltration present. Consecutive tumor sections 
were stained with antibodies against human T-cells (CD3, CD4, CD8), B-cells 
(CD20), macrophages (CD68), neutrophils (MPO, CD66b) and natural killer cells 
(NCAM). Stained sections were screened at low power (100x) to identify 5 areas with 
the highest density of positive cells (hot spots). Next, at each hot spot, an image was 
taken at 400x magnification (high power field, HPF) and the absolute number of 
positive cells per hotspot surface was counted manually to obtain the average density 
of positive cells per 5 HPFs (positive cells/mm2). 
Statistical analyses 
Methylation analyses were performed on normalized "-values. Top-down 
unsupervised hierarchical clustering was performed using a recursively partitioned 
mixture model (RPMM).13 Multivariate logistic regression models with forward 
stepwise selection assessed age, histological subtype, pack-years smoked, years-quit 
smoking, COPD status, emphysema, COPD treatment and batch as independent 
predictors. Differential methylation was assessed between tumor and adjacent lung 
tissue in the entire study population, in COPD and non-COPD subgroups. We used a 
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paired linear model for differential methylation assessment (Limma). A CpG site was 
differentially methylated when exhibiting a false discovery rate (FDR)-adjusted P-
value <0.05 and a difference in "-value between tumor and adjacent lung tissue (#"-
value) >0.075.14 Differential expression analysis was performed using DESeq 
following normalization with EDASeq. A two-fold or greater change in expression 
and FDR<0.05 were selected to designate significantly up- or downregulated genes. 
Gene ontology (GO) enrichment analysis was performed using GOrilla. Only GO-
terms with a FDR<0.05 were considered as significantly enriched. The association of 
COPD with the number of tumor-infiltrating immune cells was assessed by linear 
regression adjusted for covariates. Statistical analyses were performed using SPSS 
software (v19.0) and R (v2.14.1). 
 
RESULTS 
Novel NSCLC subtypes based on DNA methylation profiling 
We included 49 NSCLC patients that underwent curative-intent surgery. Tissue pairs 
from 3 patients were excluded due to low signal intensities for some methylation 
probes, as described in the online supplement. Clinical characteristics of the 
remaining 46 patients are shown in table 1. 
Pairwise comparison of methylation values between tumor and adjacent lung 
tissue (Δ"-values) revealed tumor-associated methylation changes similar to those 
previously described (see online supplementary results and figure S1).15 For instance, 
tumor-associated hypermethylation occurred 3 times more frequently in gene 
promoters targeted by Polycomb group proteins than in other promoters (i.e., 26.9% 
versus 8.8%, P<0.001).16 
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To subsequently identify novel NSCLC subtypes, unsupervised RPMM-based 
clustering of all tumor "-values that passed quality control was performed, revealing 
two major clusters (figure 1; online supplementary results and table S1). Forward-
logistic regression established an independent association between tumor cluster 
membership and COPD status (P=0.024), but not with other covariates in the 
regression model (age, histological subtype, pack-years smoked, years-quit smoking, 
emphysema, COPD treatment and batch). More specifically, we found that one cluster 
was significantly enriched in COPD patients (15/19 or 78.9% versus 12/27 or 44.4%; 
table 1). Similarly, clustering of "-values in adjacent lung tissue also revealed two 
clusters, one of which was enriched in COPD patients (78.6% versus 50.0%). COPD 
status did, however, not significantly influence cluster membership, as assessed by 
forward-logistic regression (online supplementary table S2). There was no association 
between other clinical variables and cluster membership. Additionally, no overlap in 
cluster membership between the tumor- and adjacent tissue-based clusters was noted. 
Differential methylation according to COPD status 
Since COPD status differed significantly between cluster subgroups, we stratified our 
study population by COPD status. Clinical characteristics of COPD and non-COPD 
subgroups are presented in online supplementary table S3. First, to identify COPD-
associated methylation events, we compared for each CpG the "-values between 
tumor versus adjacent lung tissue in the COPD and non-COPD subgroup separately. 
Subsequently, we selected for both subgroups those CpGs that displayed a significant 
difference in Δ"-value (Δ">0.075 and FDR<0.05 using a paired linear model; online 
supplementary table S1) and performed a GO enrichment analysis. In the COPD 
subgroup, genes with CpGs that were hypermethylated in tumor versus adjacent tissue 
were enriched for GO terms involved in immune response activation, whereas no 
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enrichment was observed in the non-COPD subgroup (figure 2A,C). On the other 
hand, genes with hypomethylated CpGs were not enriched for GO terms in the COPD 
subgroup, whereas a diverse set of GO processes was identified in the non-COPD 
subgroup (figure 2B,D).  
To assess whether the enrichment for immune response genes in COPD 
patients originated from tumor or adjacent lung tissue, we directly compared tumor "-
values between patients with and without COPD. GO analysis of genes relatively 
hypermethylated in COPD tumors (P<0.05; online supplementary table S1) confirmed 
that these genes were significantly enriched for immune genes. When comparing 
adjacent lung tissue between both subgroups, no enrichment for GO terms was found, 
which is in accordance with the less-pronounced differences in methylation-based 
clusters in adjacent lung tissue. Hence, hypermethylation of immune response genes 
in COPD patients specifically affects the tumor tissue.  
In a next step, we assessed whether the immune signature in COPD tumor 
tissue was attributable to a difference in the amount of immune cells infiltrating the 
tumor or to differential methylation of immune-related genes expressed by tumor 
cells. We found evidence for both mechanisms. In particular, using the 
Immunological Genome Project database,17 we found that genes specifically 
expressed by immune cells, such as CD4, which is expressed by mature T-helper 
cells, exhibited promoter hypermethylation in COPD tumors. Since promoters of 
expressed genes are usually not methylated, their high methylation status in COPD 
tumors suggests that there is reduced infiltration of immune cells in these tumors. For 
other immune genes, we found published evidence that they are predominantly 
expressed in tumor cells and that changes in their expression levels influence the anti-
tumor immune response. These genes included CCL5, encoding a chemo-attractant; 
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TNFRSF21, encoding a member of the TNF receptor superfamily; and SUSD2, 
influencing tumor infiltration by CD4-positive lymphocytes. Hypermethylation of the 
latter genes in COPD patients is therefore likely to occur in tumor cells. 
Methylation-driven gene expression changes 
Next, to investigate the impact of tumor-associated DNA hypermethylation on gene 
expression, we sequenced mRNA of 39 tumor-normal pairs (other pairs failed RNA 
quality control assessment; see online supplementary results). On average, 36.0 
million sequence reads were generated per sample and 69.4% of coding genes were 
expressed. 
Given the observed differences in methylation between tumors in COPD and non-
COPD patients, we stratified expression data for COPD status (21 and 18 patients 
with and without COPD, respectively; online supplementary table S4). Moreover, 
since immune response genes were hypermethylated in COPD tumors and DNA 
hypermethylation of gene promoters results in silencing of the associated gene, we 
focused on genes downregulated in tumor versus adjacent tissue (FDR<0.05; online 
supplementary table S1). GO-analysis of genes characterized by reduced expression 
in the tumor revealed a strong enrichment of immune genes in the COPD subgroup 
only, confirming that the observed hypermethylation events in COPD tumors were 
relevant at the expression level (figure 3A,B). Notably, also after correcting for 
COPD treatment, GO analysis revealed the same enrichment for immune genes. In 
adjacent tissue, gene expression changes did not show enrichment for immune-related 
GO terms in COPD versus non-COPD patients, although a significant enrichment in 
immune-related GO terms among genes significantly downregulated (P<0.05) was 
noted in adjacent tissue from treated versus non-treated COPD patients (online 
supplementary figure S2), as reported previously.18 However, since a less stringent P-
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value threshold was used to select downregulated genes in this analysis, this effect is 
clearly less pronounced than the immune-related signature in COPD tumors. 
Next, we integrated DNA methylation and RNA sequencing data obtained 
from COPD patients (online supplementary figure S3). Since GO terms were not 
enriched in hypomethylated genes when comparing COPD tumor versus adjacent 
lung tissue, we focused on hypermethylated genes. Of the 1,985 genes with promoter 
hypermethylation in tumor versus adjacent tissue (FDR<0.05), we identified 311 
genes whose expression was more than two-fold downregulated in tumor versus 
adjacent tissue of COPD patients (FDR<0.05; online supplementary table S1). These 
contained 76 immune-related genes (figure 4A,B). 
Validation of an immune-specific signature in lung cancer patients with COPD 
As an independent validation of the COPD-specific expression signature, we used 
TCGA expression data of 178 NSCLC patients for whom spirometry data were 
available.19 After stratification of this cohort for COPD status (46 patients with and 
132 patients without COPD; online supplementary table S5), GO analysis of genes 
downregulated in tumor versus adjacent tissue (FDR<0.05; online supplementary 
table S1) confirmed the enrichment of immune genes in the COPD subgroup, thus 
independently validating the presence of an immune-specific signal in COPD tumors 
(figure 3C,D).  
Finally, we also assessed which immune genes were downregulated in tumor 
versus adjacent tissue from COPD patients both in our discovery and validation 
cohort (FDR<0.05 in both cohorts). Remarkably, of the 535 genes that were 
significantly downregulated in COPD tumors in both cohorts, 161 genes were 
associated with an immune-related GO term (online supplementary table S1). 
Interestingly, of the 311 genes that were both hypermethylated and downregulated in 
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our discovery cohort, 125 genes were also downregulated in tumor versus adjacent 
tissue in the validation cohort (FDR<0.05). Genes were involved in the innate defense 
response (AGER), lung dendritic cell trafficking (CCRL2), lymphocyte migration 
(S1PR1), etc. (figure 5). 
Histopathology of immune cell infiltrates in COPD versus non-COPD tumors 
We also quantified infiltrating immune cells using histopathology. First, an 
experienced pathologist estimated the degree of immune cell infiltration on H&E-
stained sections from all 49 tumors selected for methylation profiling. This revealed 
significantly less immune cell infiltration in COPD patients (P=0.036; figure 6A-C; 
online supplementary figure S4). Multivariable-adjusted logistic regression confirmed 
that this effect was independent from covariates (P=0.022). 
Secondly, we stained consecutive tumor sections for established T-cell (CD3, CD4, 
CD8), B-cell (CD20), neutrophil (MPO, CD66b), macrophage (CD68) and natural 
killer cell (NCAM) markers. Multivariable-adjusted linear regression revealed a 
significant association between COPD status and the average density of CD3-positive 
T-cells (P=0.001). In particular, tumors from COPD patients contained fewer CD3-
positive T-cells (figure 6D-F). There was a similar correlation between COPD status 
and the density of CD4-positive cells (P=0.012; figure 6G-I). CD4 is commonly used 
as a T-helper (TH) cell marker. However, it can also be expressed by other immune 
cells, such as macrophages. The fact that we observed reduced infiltration for both 
CD3- and CD4-positive cells suggests that infiltration of CD4-positive TH-cells in 
COPD tumors was reduced. This was confirmed microscopically based on typical TH-
cell morphology. Furthermore, there were no significant differences observed for the 
CD68 macrophage-specific marker (online supplementary figure S5). 
 
! "'!
 Finally, to elucidate whether specific TH-cell subtypes were affected, we re-
analyzed gene expression data from the discovery cohort. In particular, by assessing 
TH-cell subtypes (TH1, TH2, TH9, TH17, TH22, regulatory (TReg) and follicular (TFH) T-
cells) using a published marker set20 (online supplementary table S6), we observed 
that global expression of TH-cell markers in COPD tumors was indeed reduced 
(P=0.018). Particularly, at the individual TH-cell subtype level, expression of TReg 




We studied 49 pairs of surgically-resected tumors and adjacent tissues using genome-
wide methylation profiling. Unsupervised clustering of tumor data identified two 
subgroups that represented different populations in terms of COPD status. Although 
other clinical covariates are also likely to affect the methylation profile of the tumor, 
our data suggest that the effect of COPD is stronger than that of age, smoking 
behavior, emphysema and histopathological subtype. This is surprising, because age 
and smoking are major risk factors for NSCLC, and because histopathology reflects 
the difference in cell type affected by the carcinogenic process, whereby cell type 
identity is a well-known determinant of DNA methylation. In the adjacent tissue, no 
such difference was observed in COPD versus non-COPD patients, thereby 
confirming previous DNA methylation and gene expression studies.21-26 Only when 
stratifying for COPD treatment, a weak enrichment in immune-related GO terms was 
observed for genes downregulated in the adjacent tissue of the treated subgroup of 
COPD patients, as reported by others!18 COPD thus seems to more strongly affect 
DNA methylation of tumor than of normal tissue. 
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Stratification for COPD status revealed that epigenetic events in COPD-
associated NSCLC were enriched for immune-related genes. This was attributable to 
a relative hypermethylation of immune genes either predominantly expressed by 
tumor-infiltrating immune cells or by tumor cells. Promoters of genes expressed by 
immune cells are mostly unmethylated, but may become hypermethylated (and thus 
not expressed) in tumor cells. A higher methylation status of such genes thus suggests 
that there is reduced infiltration of immune cells in the tumor. This was indeed 
confirmed by immunohistopathology. Combined with our observation that also 
immune genes predominantly expressed by tumor cells were hypermethylated, these 
findings suggest that COPD tumors are characterized by a less pronounced immune 
response. 
Since COPD lungs are characterized by increased immune cell infiltration 
and excessive chronic inflammation,27 these findings may look surprising. However, 
often the immune system of COPD patients is largely dysfunctional. Their 
macrophages, for instance, exhibit deficient phagocytic functions towards apoptotic 
epithelial cells and bacteria, thereby sustaining chronic inflammation and 
predisposing to infections that are characteristic of severe COPD.27-30 The immune 
system in COPD patients may thus not be capable of mounting an effective immune 
response against the tumor. As a result, in COPD tumors, the infiltration of TH-cells 
will be less pronounced, which will further weaken anti-tumor immunity, as TH-cells 
are essential for inducing a strong immune response. Accordingly, the more 
pronounced downregulation of markers for TReg-cells, which in principle have a 
tumor-associated immunosuppressive effect, supports the hypothesis that COPD 
tumors are less dependent on immunosuppression. 
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Overall, we thus identified a NSCLC subtype characterized by reduced 
immune cell infiltration and associated with COPD status. Interestingly, cancer 
subtypes characterized by differential expression of immune response genes have 
previously been established as predictors of treatment response and survival in other 
cancers.31-33 Future studies assessing novel NSCLC treatment strategies!should thus 
take COPD status or reduced immune cell infiltration as a potential predictive 
biomarker into account. Especially when testing cancer immunotherapies, COPD 
status might have to be considered. Very recently, the FDA approved the anti-PD-1 
therapy, nivolumab, as the first immunotherapy for metastatic NSCLC.34 It would 
obviously be very interesting to assess whether NSCLC patients respond differently to 
this novel therapy depending on their COPD status. 
Although methylation profiling studies have previously been conducted for 
NSCLC tumors, our study is unique in several respects. First of all, our patient 
population was extensively phenotyped and for the first time included COPD status as 
a covariate (online supplementary table S7). Secondly, adjacent non-malignant lung 
tissue was collected for each tumor sample, allowing us to correct for inter-individual 
epigenetic variation due to aging and smoking. Indeed, immune-related GO terms 
were more enriched when analyzing #"-values than tumor "-values. A potential 
limitation is that there were no methylation data publically available to replicate our 
clustering results. Additionally, as it is virtually impossible to collect lung tissue from 
cancer-free non-COPD patients (because these patients do not undergo surgery), we 
were forced to compare COPD versus non-COPD adjacent lung tissue from NSCLC 
patients undergoing surgery. Effects of the tumor on the adjacent resection specimen 
can thus not formally be excluded. Finally, systemic corticosteroid use has been 
shown to influence DNA methylation in COPD patients.35 However, although other 
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COPD treatments also affected gene expression, we were not able to explore this 
specifically for systemic corticosteroids given the limited number of patients treated 
(n=4). 
 Overall, our study describes the presence of a specific tumor micro-
environment in COPD-associated NSCLC, which is characterized by reduced immune 
cell infiltration, thereby providing novel insights into how lung tumors of COPD 
patients differ from those of non-COPD patients. 
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Figure 1. Unsupervised clustering of tumor !-values and heatmap representation 
of DNA methylation data. 
Left panel: RPMM-based classification of 46 NSCLC tumor samples (columns) and 
heatmap representation of the 13,965 most variable "-values (rows) between the two 
clusters (FDR<0.01 and #"-value between both clusters >0.15). "-values are 
represented by a color scale ranging from dark blue (low DNA methylation) to bright 
yellow (high DNA methylation). Clustering revealed two tumor clusters (n=27 and 
n=19 for cluster 1 and 2, respectively), which differed according to COPD status, as 
indicated above the heatmap. Samples from COPD patients are indicated in red above 
the heatmap, adenocarcinoma samples are indicated in blue and patients receiving 
COPD treatment are indicated in orange. Continuous variables (age, pack-years 
smoked and years-quit smoking) and the degree of emphysema are represented by 
color scales (respectively, black, purple, green and turquoise) ranging from light (low 
number) to dark (high number). Right panel: For comparison, a heatmap 
representation of the 13,965 "-values identified by clustering of tumor "-values (left 
panel) in the 46 adjacent non-malignant lung tissues is shown. All adjacent lung tissue 
samples have comparable methylation values for the selected tumor-associated CpGs.  
 
Figure 2. GO terms enriched in genes differentially methylated in NSCLC 
patients with and without COPD. 
GO enrichment analysis was performed on genes containing significantly 
differentially methylated "-values in tumor versus adjacent tissue in the COPD 
subgroup (left panel) or in the non-COPD subgroup (right panel). Left panel: For the 
! #'!
COPD subgroup: (A) the 5 most significantly enriched GO terms among the 546 
hypermethylated genes are presented; (B) no GO enrichment was identified among 
the 2,154 hypomethylated genes. Right panel: For the non-COPD subgroup: (C) no 
GO enrichment was identified among the 1,835 hypermethylated genes; (D) the 5 
most significantly enriched GO terms among the 1,169 hypomethylated genes are 
presented. Horizontal bars represent the fold enrichment (X-axis) for the significantly 
enriched GO terms, and bars for GO terms associated with immunological processes 
are red. The FDR-values for enrichment, the number of differentially methylated 
genes associated with a specific GO term (n), and the ratio of n and the total number 
of genes associated with a specific GO term (%) are provided at the right of the 
associated bars.  
 
Figure 3. GO terms enriched in genes differentially expressed in NSCLC patients 
with and without COPD. 
GO enrichment analysis was performed on genes significantly downregulated in 
tumor versus adjacent lung tissue from NSCLC patients with COPD (n=445 genes, A) 
and without COPD (n=295 genes, B) in our RNA-seq discovery cohort (left panel); 
and on genes significantly downregulated in tumor versus adjacent lung tissue from 
NSCLC patients with COPD (n=34 genes, C) and without COPD (n=698 genes, D) in 
the RNA-seq TCGA validation cohort (right panel). The 5 most significantly enriched 
GO terms for each subgroup are presented. Horizontal bars represent the fold 
enrichment (X-axis) for the significantly enriched GO terms, and bars for GO terms 
associated with immunological processes are red. The FDR-values for enrichment, the 
number of differentially expressed genes associated with a specific GO term (n), and 
! #(!
the ratio of n and the total number of genes associated with a specific GO term (%) 
are provided at the right of the associated bars.  
 
Figure 4. Integration of DNA methylation and gene expression changes. 
Box plots showing changes in promoter DNA methylation (A) and gene expression 
(B) between tumor tissue (grey boxes) and adjacent lung tissue (white boxes) from 
NSCLC patients with COPD for 12 immune genes found to be both promoter 
hypermethylated and downregulated, including CD157 involved in migration of 
neutrophils to the inflammation site and CCRL2 involved in lung dendritic cell 
trafficking and priming of a T-helper cell response. The Y-axis represents the mean 
promoter "-value (A) and the gene expression as the log2-transformed fold change 
over median gene expression level for each sample (B) for the selected genes. The 
box represents the interquartile ranges. The line across the box indicates the median. 
The whiskers extend from the box to the 90th and 10th percentiles, excluding outliers. 
Outliers (open circles) are defined as cases outside the 90th and 10th percentiles. For 
all selected genes, both methylation and gene expression differed significantly 
between tumor and adjacent lung tissue from COPD patients (FDR-adjusted P-values 
<0.05). 
 
Figure 5. Expression of selected immune markers downregulated in the RNA-seq 
discovery and validation cohort. 
Box plots showing gene expression levels of 12 immune genes with a significantly 
lower expression level in tumor tissue from COPD patients (grey boxes) versus tumor 
tissue from non-COPD patients (white boxes), both in the discovery and TCGA 
validation cohort (FDR<0.05 for both). The Y-axis represents the gene expression as 
! #)!
the log2-transformed fold change over median gene expression level for each sample. 
The box represents the interquartile ranges. 
Figure 6. Fewer tumor-infiltrating immune cells in COPD versus non-COPD 
patients. 
(Top panel) Representative microscopic pictures showing different degrees of 
immune cell infiltration in H&E stained tumor sections. (A) Tumor section with 
mainly fibrosis (indicated by the white arrow) and a low density of immune cell 
infiltrates between tumor cell nests (some of which are marked by a white asterisk). 
This section is representative for tumor sections with no-to-mild immune cell 
infiltration. (B) Tumor section with pronounced immune cell infiltration (indicated 
by the white arrow) between the tumor cell nests (some of which are marked by a 
white asterisk). This section is representative for tumor sections with moderate-to-
severe immune cell infiltration. (C) Stacked bar plot showing the proportion of 
tumors showing no-to-mild versus moderate-to-severe (colored in grey) immune 
cell infiltration between COPD and non-COPD patients. A significantly higher 
proportion of COPD tumors showed no-to-mild immune cell infiltration.  
(Middle panel) Representative pictures of tumor sections from COPD (D) and non-
COPD patients (E) stained with an antibody directed against CD3. Positive cells are 
colored brown. (F) Dot chart showing the density of tumor-infiltrating CD3-positive 
cells in COPD versus non-COPD patients. The Y-axis represents the average 
density of positive cells per 5 high power fields (HPFs). The horizontal black bar 
represents the mean.""
(Lower panel). Representative pictures of tumor sections from COPD (G) and non-
COPD patients (H) stained with an antibody directed against CD4. Positive cells are 
colored brown. (I) Dot chart showing the density of tumor-infiltrating CD4-positive 
! #*!
cells in COPD versus non-COPD patients. The Y-axis represents the average 
density of positive cells per 5 high power fields (HPFs). The horizontal black bar 
represents the mean. Asterisks (*) indicate P<0.05. Original magnifications: x50 
(A,B) and x400 (D,E,G,H). Scale bar, 200$m (upper panel) and 50$m (middle and 
lower panel). 
! #+!
TABLE 1. Clinical characteristics of the study population and of DNA 
methylation-based tumor clusters 
 
 Total Cluster 1 Cluster 2 
Subjects, n (%)  46 27 (58.7) 19 (41.3) 
Demographics    
Age, years, mean (SD) 67.0 (8.0) 66.1 (8.4) 68.3 (7.4) 
Male sex, n (%) 39 (84.8) 23 (85.2) 16 (84.2) 
Smoking behavior    
Pack-years history, mean (SD) 44.3 (23.4) 44.4 (27.0) 44.1 (17.8) 
Smoked years, mean (SD) 43.0 (12.7) 40.4 (13.2) 46.8 (11.2) 
Current smokers, n (%) 29 (63.0) 16 (59.3) 13 (68.4) 
COPD, n (%) 27 (58.7) 12 (44.4) 15 (78.9) 
COPD GOLD stage, n (%)    
stage I 11 (23.9) 4 (33.3) 7 (46.7) 
stage II 15 (32.6) 8 (66.7) 7 (46.7) 
stage III 0 (0.0) 0 (0.0) 0 (0.0) 
stage IV 1 (2.2) 0 (0.0) 1 (6.7) 
Histologic type, n (%)    
Adenocarcinoma 25 (54.3) 16 (59.3) 9 (47.4) 
Squamous cell 21 (45.7) 11 (40.7) 10 (52.6) 
Tumor stage, n (%)    
IA 11 (23.9) 4 (14.8) 7 (36.8) 
IB 9 (19.6) 5 (18.5) 4 (21.1) 
IIA 9 (19.6) 6 (22.2) 3 (15.8) 
IIB 6 (13.0) 5 (18.5) 1 (5.3) 
IIIA 9 (19.6) 6 (22.2) 3 (15.8) 
IV 2 (4.3) 1 (3.7) 1 (5.3) 
COPD Treatment, n (%) 16 (34.8) 9 (33.3) 7 (36.8) 
LAMA 7 (15.2) 5 (18.5) 2 (10.5) 
LABA 1 (2.2) 1 (3.7) 0 (0.0) 
ICS 14 (30.4) 8 (29.6) 6 (31.6) 
CS 4 (8.7) 3 (11.1) 1 (5.3) 
Emphysema, n (%)    
None 10 (21.7) 5 (18.5) 5 (26.3) 
Mild 27 (58.7) 17 (63) 10 (52.6) 
Moderate 8 (17.4) 5 (18.5) 3 (15.8) 
Severe 1 (2.2) 0 (0.0) 1 (5.3) 
Categorical variables are expressed as number (n) and percentage (%). Percentages 
represent column percentages. Continuous variables are expressed as mean and standard 
deviation (SD). Abbreviations: COPD, Chronic Obstructive Pulmonary Disease; 
GOLD, Global Initiative for Chronic Obstructive Lung Disease; LAMA, long-acting 
muscarinic antagonists; LABA, inhaled long-acting ? 2-agonists; ICS, inhaled 
corticosteroid; CS, oral corticosteroids. Clusters were determined by RPMM-based 
clustering of normalized tumor "-values.  
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